In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
The company also plans to register the similar range of products in the neighbouring countries.
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
India produces 60% of the world’s vaccine
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Subscribe To Our Newsletter & Stay Updated
